Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 17:51 ET | Source: Bragar Eagel & Squire

UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options If you purchased or...
April 02, 2026 16:58 ET | Source: FemiPro

FemiPro Claims Evaluated: Bladder Control Support with Clinically-Research Ingredients for Women's Urinary Microbiome Benefits

FemiPro 2026 consumer release: bladder control supplement ingredients, probiotic research, cranberry extract science, pricing, and buyer details.
April 02, 2026 16:46 ET | Source: The Rosen Law Firm PA

INO FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October...
April 02, 2026 16:11 ET | Source: Hagens Berman Sobol Shapiro LLP

QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
April 02, 2026 16:05 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
April 02, 2026 16:05 ET | Source: Minerva Neurosciences, Inc

Minerva Announces Leadership Transition

BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
April 02, 2026 16:05 ET | Source: Athyrium Capital Management, LP

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Athyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka’s bempedoic acid products, together with related milestone payments, subject to a cap, for total...
April 02, 2026 16:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion’s Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued...
April 02, 2026 15:54 ET | Source: PawPrint Labs

PawPrint Protocol Claims Evaluated: The Most Effective Liquid Dog NAD+ NMN Supplement for Pets

PawPrint Protocol NAD+ NMN nanoliposomal liquid dog supplement: ingredient research, dosing, pricing, and 90-day guarantee details for 2026.
April 02, 2026 15:26 ET | Source: MediWound Ltd.

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...